Thursday, May 4, 2017

Lantern Pharma Gets $3.7M

Dallas-based Lantern Pharma announced this week that it has raised $3.7M in a funding round, to go towards its clinical-stage cancer treatments. The funding was led by Bios Partners, GPG Ventures, and other private investors. Lantern Pharma says it is using big data and artificial intelligence to help revive "abandoned" drugs from partners with late-stage, clinical drugs, where only a small number of patients responded to treatment. The company says it uses molecular profiling to identify those patients that would respond to those particular treatments. More information »